Tagraxofusp-erzs OverviewTagraxofusp-erzs (trade name Elzonris) is a drug for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). It was approved for use in the United States in 2018. Tagraxofusp-erzs is a fusion protein consisting of interleukin 3 (IL-3) fused to diphtheria toxin. The fusion protein readily kills cultured pDC by binding to their IL-3 receptors to thereby gain entrance to the cells and then blocking these cells' protein synthesis (due to its d...
Read more Tagraxofusp-erzs Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Tagraxofusp-erzs
Recent Tagraxofusp-erzs Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Solution: 1000mcg
Other drugs which contain Tagraxofusp-erzs or a similar ingredient: (1 result)
- ELZONRIS Tagraxofusp-erzs